Twelve months after revaccination, antibody levels declined but remained significantly higher than baseline in patients with CLL.

VAX-31 has the potential to be "a best-in-class pneumococcal vaccine capable of raising the bar for immunogenicity standards," he added. The company is also developing a 24-valent pneumococcal ...

The study is evaluating the effectiveness of VAX-24 compared to Pfizer's (NYSE:PFE) Prevnar 20 vaccine. One reason for the dramatic decline is likely the impending departure of Peter Marks ...

The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

tolerability and immunogenicity of VAX-24, the Company’s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20 ...

At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial ...

That's because the positive data reinforces that VAX-24 as a pneumococcal vaccine candidate may end up being better than that of Pfizer's (PFE) Prevnar 20 [PCV]. This tees up the company to ...

The CDC’s ACIP updated guidance on pneumococcal vaccination, recommending a single dose of PCV for all adults aged 50 years and older.

Last week, Vaxcyte reported top-line results from the mid-stage study that evaluated its 24-valent PCV VAX-24 against Pfizer’s PFE Prevnar 20. The Pfizer vaccine is approved for preventing ...

At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20 ® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune ...

The FDA has approved a new pneumococcal vaccine from Merck & Co, just over a month after Pfizer got a green light for a new version of its market leading Prevnar shot. Merck's Vaxneuvance ...